These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29545339)

  • 1. The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study.
    Oortgiesen BE; Azad R; Hemmelder MH; Kibbelaar RE; Veeger NJGM; de Vries JC; van Roon EN; Hoogendoorn M
    Haematologica; 2018 Jul; 103(7):e311-e314. PubMed ID: 29545339
    [No Abstract]   [Full Text] [Related]  

  • 2. A population-based study of the impact of dialysis on mortality in multiple myeloma.
    Evison F; Sangha J; Yadav P; Aung YS; Sharif A; Pinney JA; Drayson MT; Cook M; Cockwell P
    Br J Haematol; 2018 Feb; 180(4):588-591. PubMed ID: 27766629
    [No Abstract]   [Full Text] [Related]  

  • 3. Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure.
    Moore DC; Arnall JR; Janes A; Pineda-Roman M
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e395-e398. PubMed ID: 32359768
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma.
    Rocchi S; Tacchetti P; Pantani L; Mancuso K; Zannetti B; Cavo M; Zamagni E
    Haematologica; 2018 Jun; 103(6):e277-e278. PubMed ID: 29622654
    [No Abstract]   [Full Text] [Related]  

  • 5. Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014.
    Laforet M; Jourde-Chiche N; Haddad F; Sallee M; Stoppa AM; Brunet P; Dussol B; Burtey S; Gondouin B
    Blood Cancer J; 2016 Mar; 6(3):e409. PubMed ID: 27015286
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies.
    Zhu W; Chen W
    Medicine (Baltimore); 2016 Nov; 95(46):e5202. PubMed ID: 27861343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
    Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Rekhtman G; Masliak Z; Robak P; Esseltine DL; Feng H; Deraedt W; van de Velde H; Arnulf B
    Haematologica; 2015 May; 100(5):e207-10. PubMed ID: 25596270
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcome of patients with multiple myeloma and renal failure on novel regimens.
    Soleymanian T; Soleimani A; Musavi A; Mojtahedi K; Hamid G
    Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):335-40. PubMed ID: 26997388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function.
    Chen J; Liu H; Li L; Liu Z; Song J; Wang G; Wang H; Ruan E; Ding K; Shao Z; Fu R
    J Clin Lab Anal; 2019 Jun; 33(5):e22888. PubMed ID: 31004381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
    An N; Li X; Shen M; Chen SL; Huang ZX
    Zhonghua Nei Ke Za Zhi; 2016 Oct; 55(10):764-768. PubMed ID: 27686436
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.
    Uttervall K; Duru AD; Lund J; Liwing J; Gahrton G; Holmberg E; Aschan J; Alici E; Nahi H
    PLoS One; 2014; 9(7):e101819. PubMed ID: 25003848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
    Reneau JC; Asante D; van Houten H; Sangaralingham LR; Buadi FK; Lerman A; Herrmann J
    Am J Hematol; 2017 Feb; 92(2):E15-E17. PubMed ID: 27813147
    [No Abstract]   [Full Text] [Related]  

  • 13. [Achievement of hemodialysis discontinuation with lenalidomide and dexamethasone therapy in a refractory BJP-type multiple myeloma patient].
    Uchida T; Inoue M; Hua J; Hagihara M
    Rinsho Ketsueki; 2016 May; 57(5):613-7. PubMed ID: 27263787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
    Dimopoulos MA; Merlini G; Bridoux F; Leung N; Mikhael J; Harrison SJ; Kastritis E; Garderet L; Gozzetti A; van de Donk NWCJ; Weisel KC; Badros AZ; Beksac M; Hillengass J; Mohty M; Ho PJ; Ntanasis-Stathopoulos I; Mateos MV; Richardson P; Blade J; Moreau P; San-Miguel J; Munshi N; Rajkumar SV; Durie BGM; Ludwig H; Terpos E;
    Lancet Oncol; 2023 Jul; 24(7):e293-e311. PubMed ID: 37414019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Update in multiple myeloma: international criteria for treatment response and renal complications].
    Decaux O; Karras A
    Rev Med Interne; 2009 Dec; 30(12):1080-3. PubMed ID: 19833418
    [No Abstract]   [Full Text] [Related]  

  • 16. Current treatments for renal failure due to multiple myeloma.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2016 Nov; 17(16):2165-2177. PubMed ID: 27646819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple myeloma presenting with advanced renal failure: a case report and new treatment options.
    Gladney SP; Lonial S; Kaufman JL
    Clin Lymphoma Myeloma; 2008 Feb; 8(1):52-4. PubMed ID: 18501088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dialysis-dependent renal failure in patients with multiple myeloma: Reversibility factors].
    Rekhtina IG; Mendeleeva LP; Biryukova LS
    Ter Arkh; 2015; 87(7):72-76. PubMed ID: 26390728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment.
    Liu A; Yang G; Geng C; Wang H; Li L; Li Y; Wu Y; Tian Y; Leng Y; Wang G; Gao W; Chen W
    Acta Haematol; 2016; 135(3):140-5. PubMed ID: 26587903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
    Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.